

Memantine (Ebixa[®])

(No. 57/03)

Lundbeck Ltd

Summary of Recommendation

11 August 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE

Not recommended for use within NHS Scotland.

RECOMMENDATION

Although this is currently the only agent licensed for use in moderately severe to severe Alzheimer's disease, the magnitude of the effect is extremely small. Compared with placebo it is associated with a statistically significant reduction in the rate of deterioration in global, functional and cognitive scales. On the evidence presented, the associated gains appear to be marginal relative to the overall costs.

The license holder has indicated their decision to resubmit.

Professor David H Lawson
Chairman